Skip to main content
. 2023 Aug 18;66(17):12237–12248. doi: 10.1021/acs.jmedchem.3c00810

Figure 1.

Figure 1

Clinical-stage inhibitors of Mpro and a panel of initial peptidomimetic inhibitors. (A) Covalent inhibitors of Mpro that are clinically used or underwent clinical evaluation. (B) General design of a panel of peptidomimetic inhibitors featuring various electrophilic warheads, including α,β-unsaturated ester, vinylsulfone, vinylsulfonamide, terminal alkyne, aldehyde, ketoamide, and nitrile.